TRT, tren, and HGH claims: what the science actually supports

What did @coach.agz actually say?

The creator pitched three anabolic compounds as the foundation of a "health-focused" enhanced protocol: testosterone, something called "pre-mobilin" (almost certainly a mispronunciation of primobolan, the brand name for methenolone), and nandrolone phenylpropionate (NPP). The framing was that smart athletes optimize for "maximum output with minimum health cost," and these three compounds supposedly deliver that without requiring an aromatase inhibitor when dosed intelligently together.

He made specific claims: testosterone improves insulin sensitivity and cardiovascular efficiency, primobolan enhances immune function through "angiogenic receptor activation," has no liver stress as an injectable, and no DHT conversion pathway damage. For NPP, he argued it directly drives collagen synthesis and synovial fluid production at rates "no other anabolic compound does," and that it has preferential binding in muscle tissue over androgenic tissue.

Does the science back this up?

Partially, but with significant caveats the creator glossed over. Testosterone's metabolic effects are real but dose-dependent and context-dependent. Nandrolone's collagen synthesis data has some legitimate backing. The primobolan claims, however, are a mixed bag of plausible pharmacology and invented terminology that you won't find in any peer-reviewed paper.

On testosterone: there is genuine research supporting improvements in insulin sensitivity in hypogonadal men. Wittert et al. (2021, New England Journal of Medicine) showed testosterone treatment reduced type 2 diabetes incidence in high-risk men. Cardiovascular claims are far more contested. The TRAVERSE trial (Lincoff et al., 2023, NEJM) showed non-inferiority to placebo for major cardiac events, but "cardiovascular efficiency" as a blanket benefit is an oversimplification.

On nandrolone and collagen: Michna (1986, Acta Anatomica) and Falanga et al. (1998, Archives of Dermatology) documented anabolic steroid effects on collagen synthesis, and nandrolone specifically has been studied in this context. The synovial fluid claim is harder to pin down in robust human RCT data.

On primobolan: the "angiogenic receptor" language the creator used is not standard pharmacology. Primobolan binds androgen receptors. The claim about "angiogenic receptor activation in immune cells" appears to be fabricated or severely garbled terminology.

What did they get wrong (or right)?

The creator got the basics of testosterone's metabolic role mostly right, and the NPP-over-deca argument for ester clearance speed is pharmacologically sound and a legitimate harm-reduction consideration. Shorter esters do clear faster, and that does give users more control if adverse effects appear.

But there are real problems here. First, the creator said "all of them carry significant hepatotoxic burden as injectables" and then immediately used this as a positive. That sentence is self-contradictory and likely meant to say they do NOT carry hepatotoxic burden, but as written it's a serious error that could be read as a warning or a selling point depending on the listener.

Second, the primobolan immunological claims, specifically "directly enhances immune function through angiogenic receptor activation," are not supported by published literature. Calling androgen receptors "angiogenic receptors" is either a terminology error or something invented to sound technical.

Third, the assertion that these three compounds together require no aromatase inhibitor is oversimplified. Individual aromatization rates vary significantly. Nandrolone does aromatize less than testosterone, and primobolan minimally, but blanket advice against AI use is not clinically appropriate guidance for anonymous viewers with unknown baseline hormone profiles.

What should you actually know?

None of these compounds are FDA-approved for the use cases being described. Testosterone is approved for diagnosed hypogonadism. Nandrolone (as nandrolone decanoate) is approved for anemia and specific wasting conditions in the US. Methenolone (primobolan) is not currently FDA-approved in the US at all.

Using supraphysiologic doses of anabolic steroids, which is the context of "enhanced" protocols this creator is describing, carries documented cardiovascular risks including left ventricular hypertrophy, dyslipidemia (particularly suppression of HDL), and erythrocytosis. Baggish et al. (2017, Circulation) found that long-term AAS users had significantly impaired left ventricular systolic function compared to non-users.

The creator's framing of "blood work as the standard" is actually reasonable harm-reduction logic. But recommending specific compound combinations to anonymous followers without any medical supervision is a different matter. The "500 blood work panels" framework he's offering for free via DM is not peer-reviewed and should not substitute for a physician-supervised protocol.

If you have clinically low testosterone, that is a medical condition that can be treated through legitimate TRT under physician supervision. That is categorically different from what this video is describing.